| Lauren Elaine Jacobson, MD | |
|
400 W Pueblo St, Santa Barbara, CA 93105-4353 | |
| (805) 569-7367 | |
| Not Available |
| Full Name | Lauren Elaine Jacobson |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 18 Years |
| Location | 400 W Pueblo St, Santa Barbara, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821190430 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0101X | Pathology - Anatomic Pathology | A112378 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Santa Barbara Cottage Hospital | Santa barbara, CA | Hospital |
| Goleta Valley Cottage Hospital | Santa barbara, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mission Pathology Consultants Inc | 8224152731 | 12 |
News Archive
Mayo Clinic surgical researchers are reporting a 93 percent success rate in recent animal tests of endoscopic repair of perforated ulcers. The goal is to advance the use of an endoscope - which allows access to organs through natural openings, such as the mouth - for a less invasive alternative to laparoscopic techniques (surgery performed through a small incision) or conventional surgery.
Watson Pharmaceuticals, Inc. has announced that, under a supply agreement with Solvay Pharmaceuticals, Inc., Watson has launched the authorized generic version of dronabinol in the 2.5, 5 and 10 mg once daily dosage strengths.
In an essay in The Washington Post, an infectious disease specialist writes that "the unspoken truth among doctors is that we objectively or subjectively ration care, and often don't tell patients or their families."
The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.
Patients with "masked" hypertension that is not detected by routine office blood pressure measurements appear to have stroke and death rates similar to that of patients with sustained high blood pressure; whereas patients with so-called "white coat" hypertension appear to have no greater risk than people with normal blood pressure, according to a new study in the Aug. 2, 2005, issue of the Journal of the American College of Cardiology.
› Verified 3 days ago
| Entity Name | Mission Pathology Consultants Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356409379 PECOS PAC ID: 8224152731 Enrollment ID: O20100903000542 |
News Archive
Mayo Clinic surgical researchers are reporting a 93 percent success rate in recent animal tests of endoscopic repair of perforated ulcers. The goal is to advance the use of an endoscope - which allows access to organs through natural openings, such as the mouth - for a less invasive alternative to laparoscopic techniques (surgery performed through a small incision) or conventional surgery.
Watson Pharmaceuticals, Inc. has announced that, under a supply agreement with Solvay Pharmaceuticals, Inc., Watson has launched the authorized generic version of dronabinol in the 2.5, 5 and 10 mg once daily dosage strengths.
In an essay in The Washington Post, an infectious disease specialist writes that "the unspoken truth among doctors is that we objectively or subjectively ration care, and often don't tell patients or their families."
The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.
Patients with "masked" hypertension that is not detected by routine office blood pressure measurements appear to have stroke and death rates similar to that of patients with sustained high blood pressure; whereas patients with so-called "white coat" hypertension appear to have no greater risk than people with normal blood pressure, according to a new study in the Aug. 2, 2005, issue of the Journal of the American College of Cardiology.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lauren Elaine Jacobson, MD 400 W Pueblo St, Santa Barbara, CA 93105-4353 Ph: () - | Lauren Elaine Jacobson, MD 400 W Pueblo St, Santa Barbara, CA 93105-4353 Ph: (805) 569-7367 |
News Archive
Mayo Clinic surgical researchers are reporting a 93 percent success rate in recent animal tests of endoscopic repair of perforated ulcers. The goal is to advance the use of an endoscope - which allows access to organs through natural openings, such as the mouth - for a less invasive alternative to laparoscopic techniques (surgery performed through a small incision) or conventional surgery.
Watson Pharmaceuticals, Inc. has announced that, under a supply agreement with Solvay Pharmaceuticals, Inc., Watson has launched the authorized generic version of dronabinol in the 2.5, 5 and 10 mg once daily dosage strengths.
In an essay in The Washington Post, an infectious disease specialist writes that "the unspoken truth among doctors is that we objectively or subjectively ration care, and often don't tell patients or their families."
The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.
Patients with "masked" hypertension that is not detected by routine office blood pressure measurements appear to have stroke and death rates similar to that of patients with sustained high blood pressure; whereas patients with so-called "white coat" hypertension appear to have no greater risk than people with normal blood pressure, according to a new study in the Aug. 2, 2005, issue of the Journal of the American College of Cardiology.
› Verified 3 days ago
Dr. Emily Graeme Waterhouse, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 400 W Pueblo St, Santa Barbara, CA 93105 Phone: 805-563-8333 | |
Dr. Michael Anthony Richardson, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 680 Miramonte Dr, Santa Barbara, CA 93109 Phone: 805-966-5504 Fax: 805-966-4621 | |
Mr. Michael R Repik, D.O. Pathology Medicare: Not Enrolled in Medicare Practice Location: 11 W Figueroa St, Santa Barbara, CA 93101 Phone: 805-419-5667 | |
David G Martin-reay, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: Pueblo At Bath Street, Santa Barbara, CA 93105 Phone: 805-569-7367 Fax: 805-569-8354 | |
Stewart William Comer, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 454 S. Patterson Ave, Pacific Diagnostic Laboratory, Santa Barbara, CA 92111 Phone: 805-569-7582 | |
Dr. Faith Mary Ough, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 400 W Pueblo St, Santa Barbara, CA 93105 Phone: 805-569-7367 | |
Monica Phillips, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 400 W Pueblo St, Santa Barbara, CA 93105 Phone: 805-569-7367 |